LianBio/LIAN

$4.81

0%
-
1D1W1MYTD1YMAX

About LianBio

LianBio is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing medicines for patients with unmet medical needs, with a focus on in-licensing assets for Greater China and other Asian markets. It has a pipeline of eight therapeutic candidates across cardiovascular, oncology, ophthalmology, and inflammatory disease indications. Its product candidates include Mavacamten, TP-03, NBTXR3, Infigratinib, BBP-398, Omilancor, NX-13 and LYR-210. Mavacamten is an oral small-molecule allosteric modulator of cardiac myosin, which is approved for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) and is also being studied as a treatment for other diseases of diastolic dysfunction. TP-03 is a topical ophthalmic formulation of lotilaner, that is used for the treatment of demodex blepharitis (DB) and meibomian gland disease (MGD). NBTXR3 is a radio enhancer for the treatment of head and neck cancer and other solid tumors.

Ticker

LIAN

Sector

Tervishoid

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Adam Stone

Employees

163

Headquarters

Princeton, United States

LianBio Metrics

BasicAdvanced
$517.62M
Market cap
-
P/E ratio
-$0.82
EPS
-
Beta
-
Dividend rate

What the Analysts think about LianBio

Analyst Ratings

Majority rating from 1 analysts.
Hold

Price Targets

Average projection from 2 analysts.
18.92% downside
High $4.80
Low $3.00
$4.81
Current price
$3.90
Average price target

LianBio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-24M
11.11%
Profit margin
0%
-

LianBio Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 33.33%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.17
-$0.22
-$0.20
-$0.22
-
Expected
-$0.27
-$0.27
-$0.29
-$0.33
-$0.31
Surprise
-37.61%
-19.27%
-29.82%
-33.33%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

Buy or sell LianBio stock

Buy or sell LianBio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing